Trial Profile
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms MASTERKEY-265
- Sponsors Amgen
- 23 Aug 2022 Results assessing efficacy and safety of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma, published in the Journal of Clinical Oncology
- 07 Apr 2022 This trial has been completed in Sweden and Portugal (11-03-2021), according to European Clinical Trials Database
- 05 Apr 2021 Status changed to discontinued.